

Secretariat: Santa Isabel, 51
(Ilustre Colegio de Médicos de Madrid)
Madrid 28012 España
administracion@se-fc.org

Dr. Arantxa Sancho,
EACPT Secretary
asancho.hpth@gmail.com

15th February 2021

Re: Letter of Nomination for EACPT-Lifetime Achievement Award

Dear Dr. Sancho,

We are pleased to nominate Prof. Dr. M. Isabel Lucena-González for the **EACPT 2021 Lifetime Achievement Award in Clinical Pharmacology**. Professor M. Isabel Lucena has been unanimously appointed by all members of the Executive Committee of the Spanish Society of Clinical Pharmacology as an excellent candidate due to the outstanding and continued achievements in the field of Clinical Pharmacology.

Professor M. Isabel Lucena has a degree in Medicine at Granada University, and a 3-year specialist training in clinical pharmacology and therapeutics (1980-1983). During this period, she joined the Clinical Pharmacology Department at Granada University as an assistant professor, and one year later she moved to Malaga University with the same position. In 1980 she obtained a PhD in Medicine and Surgery, with an excellent cum laude qualification and the outstanding doctorate distinction. In 1986 she was granted a full professor degree at Malaga University, where she continues actively teaching medical students as Director of the Pharmacology&Paediatrics Department (School of Medicine, University of Malaga). Her teaching experience is extended to more than 35 years, from under graduate students to post-graduate students. She has been responsible for the clinical pharmacology doctorate program and tutor in charge of clinical pharmacology training physicians during the past 30 years.

Prof. Dr M. Isabel Lucena main research area of interest is the study of drug-induced liver injury (DILI), an area where she has led an intensive research and gathered an extensive knowledge that has granted her an international prominent leading position in the field. Her main lines of research are epidemiological in DILI, the assessment of causality, stratification of risk and mechanistic factors: genetics and immunophenotyping studies, other omics and clinical trials design in order to improve the mechanistic understanding of DILI and the development of novel biomarkers and their transfer into clinical practice.

Professor Dr. M. Isabel Lucena works in close collaboration with international groups in this field and she belongs to CIBERehd, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and leads the PAIDI CTS-649 group. She is the co-investigator of IBIMA Group on Hepatogastroenterology, Pharmacology and Translational Clinical Pharmacology. She is Rapporteur of CIOMS working Group on Drug-Induced Liver Injury (DILI). Member of the Reviewing board & organizer of the Post-Graduate Course on Lifestyle and Liver Diseases for the European Association for the Study of the Liver (EASL International Liver Congress (2016-). Prof. M. Isabel Lucena is actually co-director of the EASL Postgraduate Course 2021.

Prof. M. Isabel Lucena also participates in relevant International collaborations in the field: partners in the IMI Safer and Faster Evidence Based Translation consortium (SAFE-T, 2008-2015), the International Serious Adverse Event Consortium (iSAEC), IMI2 TRANSBIOLINE project (2019-), Eurostars Programme: Novel Combo Assay for Early Detection of DILI (E!114589-LiverAce. 2021-) and leading the COST Action 17112 Prospective European Drug-Induced Liver Injury Network 2 (<https://proeurodilinet.eu>). Collaboration with Prof Kaplowitz (South California U), Susuki at Duke U, Aithal (Nottingham) and Chen M (National Centre for Toxicological Research-FDA).

With the aim to increase knowledge in the field, she founded and coordinates the Spanish DILI Registry (www.spanishdili.uma.es), a successful initiative that was followed by the foundation of the Spanish Latin-American DILI Network, and more recently the Prospective European DILI Registry awarded by EASL.

Some of these achievements are the outcome of a close and fruitful collaboration with clinical experts in the field, which should serve as an inspiring example of the value of the multidisciplinary collaborative work for the clinical pharmacology community.

Due to her outstanding knowledge in the field, she also collaborates actively with the European regulators like the Spanish Medicines and Medical devices Agency (AEMPS) and the European Medicines Agency (EMA), as an expert consultant on drug-induced liver injury and related issues.

She is frequently invited as speaker in national and international conferences, workshops, training courses and all type of meetings related to her area of interest and research, i.e. drug induced liver injury, accounting for more than 100 lectures and more than 350 works presented up to date.

The results of this intensive work is documented in more than 300 publications in peer-reviewed journals and more than 20 book chapters. She has an H-index of 44 and 6444 citations. 15 publications were cited more than 100 times and 37 original articles received more than 50 citations. She has directed 25 PhD thesis included 3 International thesis, 5 Extraordinary awards and 1 doctoral thesis co-tutelled with the University of Maastricht, Germany (defense 12thFeb.21), including also 11 final medical degree research projects.

This intensive research experience has led Professor Dr. M. Isabel Lucena to accept the current position of Scientific Director of the Clinical Pharmacology Service at the University Hospital of Malaga and Scientific coordinator of SCReN, the Platform of Clinical research and clinical trials at IBIMA (since

2013-). She was former Vice-director (2010-2013) and Scientific Director / Founder of IBIMA (Malaga Health Research Institute) (2013-2017).

She is also an active member of several professional societies. She is member of the Executive Committee of the International Union of Basic and Clinical Pharmacology. Treasurer of the Clinical pharmacology division of IUPHAR. She is member of the EACPT and places an active role in EACPT Congresses and EACPT summer courses. She is member of the SEFC, and has also been member of the Executive Committee of the Spanish Clinical Pharmacology Society (SEFC).

The Spanish Society of Clinical Pharmacology considers Prof. M. Isabel Lucena a genuine reference for all clinical pharmacologists due to her strong dedication to research and outstanding contribution to increase the knowledge in the field of drug induced liver injury; a major drug safety problem that most clinical pharmacologists face in our daily clinical practice. She is a model of well-done hard work, passion and never ending enthusiasm, commitment with the collaborative multidisciplinary research and the dissemination of knowledge. In summary, she is an inspiring clinical pharmacologist for all of us.

We are proud to nominate a candidate who keeps a strong scientific and teaching activity in clinical pharmacology and that plans to continue doing so as long as she is allowed.

Yours sincerely,

On behalf of the Executive Committee of the Spanish Society of Clinical Pharmacology



Dr. Antonia Agustí,
President of the SEFC